Biomarker Discovery in Fresh Patient Tumor Tissue

Identifying clinically significant phenotypic protein biomarkers and their biological function is a crucial step in drug development. 3D-EXplore’s holistic platform enables the exploration and quantification of biomarkers to identify and qualify responders.  



Biomarker discovery is integral to drug development because of the need to monitor the effects of investigational drugs on cancer patients during clinical trials. To combat the attrition rate of novel therapeutics in the clinic, a new generation of biomarkers that can inform researchers whether their drug or combination is efficacious before entering the clinic are being developed. Biomarkers can ultimately determine patient responsiveness to therapy so that drugs are more effectively targeted to patients, thereby improving survival rates, whilst reducing adverse-effects, treatment costs and futile therapies.


Flow Cytometry

Nilogen’s extensive experience in flow cytometry matched with our Optimized panels enable our clients to evaluate the immune landscape, T-cell activation, checkpoint inhibition, ADCCs, myeloid function, phagocytosis and cellular proliferation as well as develop and deploy custom panels.

High Content Confocal Microscopy

Quantify and match the ability of your drug to kill tumor cells with the expression of your target antigen, induce phagocytosis and measure penetration into the tumor microenvironment. Evaluate in conjunction with other proteogenomic assays to link mechanism of action with effect.

NanoString Gene Expression Analysis

We provide the complete range of NanoString  nCounter panels to study the biology of tumors, providing a fast and high-throughput multiplexed gene expression analysis of the response to therapeutic intervention in fresh patient tumors.

Single Cell RNA Sequencing

Enables the quantitative measurements of the molecular activity that underlies the phenotypic diversity of cells within a tumor by sequencing individual cells. Intratumor heterogeneity is common across all tumor types. Accurate characterization of this heterogeneity is essential for determining the mechanisms of cancer pathogenesis and identification of novel targets for immunotherapy and drug development.


TOTALseq works hand-in-hand with scRNAseq to enable the simultaneous measurement of protein and RNA at the single cell level, providing enhanced cell type identification. Evaluate the impact of drug therapy on up to 130 protein markers in conjunction with the transcriptome of each cell, enabling the single cell analysis of individual immune cells in a heterogeneous tumor microenvironment.

Multiplex Immunohistochemistry

Multiplex Immunohistochemistry/Immunofluorescence (mIHC/IF) provides high-throughput multiplex staining and standardized semi-quantitative analysis for highly reproducible, efficient and cost-effective tissue studies. This technique allows for the simultaneous detection of multiple markers on a single tissue section, providing a comprehensive view of tissue composition, pre and post treatment.

Scientific Data


Network analysis of NanoString IO360 gene expression analysis correlated with flow cytometry clusters reveals key hub genes as candidate regulators of drug response 

Related Resources

Browse our latest posters and presentations using Nilogen's fresh patient tumoroid technology.


Contact Us to Discuss Your Project requirements